

## **ANNOUNCEMENT: TWO KEY CANCER CONFERENCES**

**ABSTRACT SUBMISSION DEADLINE: MAY 30<sup>TH</sup> 2014**

**The 31<sup>ST</sup> International Conference on the Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells**  
**Date: June 23-25 , 2014**

**Venue: Santa Marina Hotel, Mykonos, Greece**

One of the longest-running conferences in the field, the meeting will include presentations by leading researchers on scientific and clinical aspects of monoclonal antibodies in clinical oncology, as well as presentations on cancer stem cells. The conference will include open-air workshops in a truly international setting conducive to networking.

Examples of speakers and preliminary topics include:

Cecile Geuijen, Merus, Netherlands: The use of bispecific antibodies to overcome resistance

Ivan Horak, Symphogen, Denmark: Antibody mixture to target tumor plasticity

Janine Schuurman, Genmab, Netherlands: Complement activation through IgG hexamers

Gerhard Niederfellner, Roche Germany: MSLN-PE cFP: The front-runner of a novel class of de-immunized cytolytic fusion proteins with high therapeutic potential towards a broad panel of solid tumors

Claudio Sustmann, Roche, Germany: cMET bsMAB: A novel recombinant antibody format to antagonize the cMET receptor

Peter Hudson, Victorian Cancer Biologics, Avipep Pty Ltd and HUPO-HAI Human Antibody Initiative, Australia: Engineered Antibody Fragments with efficient payloads for cancer diagnosis and ADC therapy

Niki Agnanti, Ioannina University, Greece: Molecular Pathology of Colorectal Cancer

Victor Goldmacher, Immunogen, USA: Antibody-Drug Conjugates (ADCs) with Novel IGN DNA-Alkylating Agents

Eugene Zhukovskiy, Affimed, Germany: Bispecific antibody platform, TandAb, for the treatment of hematological and solid tumor cancers

Michael J. Powell, Diacarta, USA: 'QClamp' a Rapid Highly Sensitive Direct Cancer Gene Somatic Mutation Detection Technology - A New Paradigm in Personalized Medicine

Steffen Goletz, Glycotope, Germany: A novel IgM against a tumor specific carbohydrate structure

**The 4<sup>TH</sup> International Conference on Notch Targeting in Cancer**

**Date: June 25-27, 2014**

**Venue: Santa Marina Hotel, Mykonos, Greece**

The fourth annual international conference devoted to Notch Biology and related Cancer Therapeutics will include basic and translational research, preclinical and clinical studies, biomarker discovery and progress achieved thus far in this emerging and exciting field of targeting Notch, as examined and presented by leading scientists in the field.

Examples of speakers and preliminary topics include:

Freddy Radtke, EPFL SV ISREC UPAD, Lausanne, Switzerland: Preclinical validation of I3 as novel Notch inhibitor.

Aleksandra Filipovic ICL and CRUK, London UK: Comparison of Notch inhibition strategies in targeting cancer cells and tumor angiogenesis

Mirko Schmidt, Johannes Gutenberg University, School of Medicine, Mainz, Germany: EGFL and Notch

Keith Brennan, University of Manchester, Manchester, UK: Activating RBPj-dependent Notch signalling in the murine mammary gland leads to spontaneous endocrine resistant ER+ve tumours

Olivier Meurette, Cancer Research Centre of Lyon (CRCL), Lyon, France: The role of Notch3 in the regulation of tumour angiogenesis

Clodia Osipo, Loyola University Chicago, Chicago, USA: The regulation of jagged and Mib-1 by HER2 in breast cancer

Robert Clarke, ICS, Manchester, UK :The role of Notch signalling in endocrine-resistant breast cancer

Wan-Ching Yen, OncoMed, Redwood City, USA :Notch pathway inhibitors in cancer stem cells and angiogenesis

Jan Kitajewski, Columbia University, USA: Targeting Dll and Jagged function in the tumor microenvironment

Dmitry Gabrilovich, The Wistar Institute, USA: Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer

---

PLEASE BOOK THE HOTEL EARLY TO GET THE MOST COST EFFECTIVE ACCOMMODATION

For further information, registration and abstract submission please contact :  
[agamemnon@epenetos.com](mailto:agamemnon@epenetos.com) or visit [www.cancerconferences.org](http://www.cancerconferences.org)